Human T-lymphotropic virus (HTLV I-II) infection among patients in an inner-city emergency department

Ann Intern Med. 1990 Sep 1;113(5):368-72. doi: 10.7326/0003-4819-113-5-368.

Abstract

Objective: To determine the seroprevalence and epidemiologic features of human T-lymphotropic virus (HTLV I-II) among an emergency department patient population with a high rate of human immunodeficiency virus (HIV-1) infection.

Design: Prospective survey using identity-unlinked consecutive sampling during a 6-week period in 1988.

Setting: Inner-city teaching hospital.

Patients: Sequential sample of 2544 adult patients with sufficient excess sera for analysis.

Measurements and main results: Twenty-eight (1.1%) (95% CI, 0.7% to 1.5%) serum samples were seropositive for HTLV I-II whereas 152 (6.0%) (CI, 5.1% to 6.9%) were seropositive for HIV-1. The age distribution of HTLV I-II was similar to the study population while HIV-1 was concentrated among younger (25 to 44 years) age groups (P less than 0.05). Only 16 (57.1%) HTLV I-II infected patients had identified risk factors; 11 were intravenous drug users, 4 received transfusions, and 1 had heterosexual exposure to a high-risk partner. None of 39 identified homosexual men had HTLV I-II antibodies although 29 (74.3%) were HIV-1 seropositive.

Conclusion: HTLV I-II infection may be more prevalent among certain segments of the U.S. population than previously realized and appears to have a different demographic distribution than HIV-1 infection. Although HTLV I-II may represent a nosocomial risk to health care providers, the risk of occupational transmission is probably less than for hepatitis B virus and even HIV-1. Adherence to universal precautions should minimize the risk.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Emergency Service, Hospital
  • Female
  • HIV Infections / complications
  • HIV Infections / epidemiology
  • HIV Infections / transmission
  • HIV Seroprevalence
  • HTLV-I Antibodies / analysis*
  • HTLV-I Infections / complications
  • HTLV-I Infections / epidemiology*
  • HTLV-I Infections / transmission
  • HTLV-II Antibodies / analysis*
  • HTLV-II Infections / complications
  • HTLV-II Infections / epidemiology*
  • HTLV-II Infections / transmission
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Risk Factors
  • United States
  • Urban Population

Substances

  • HTLV-I Antibodies
  • HTLV-II Antibodies